Literature DB >> 23245211

Age-related differences in disease characteristics and clinical outcomes in polycythemia vera.

Brady L Stein1, Santosh Saraf, Urszula Sobol, Anna Halpern, Jamile Shammo, Damiano Rondelli, Laura Michaelis, Olatoyosi Odenike, Alfred Rademaker, Anaadriana Zakarija, Brandon McMahon, Jerry L Spivak, Alison R Moliterno.   

Abstract

The natural history and prognosis for young patients with polycythemia vera (PV) in the post-JAK2 V617F era are not well defined. Therefore, we retrospectively analyzed disease characteristics and clinical outcomes in 120 patients ≤ 45 years and 84 patients ≥ 65 years at diagnosis. Despite lower white blood counts (9.2 vs. 13.4 × 10(9)/L, p = 0.004) and a lower JAK2 V617F allele burden (51% vs. 66%, p = 0.015), younger patients with PV had comparable rates of vascular complications compared to older patients (27% vs. 31%, p = 0.64). However, splanchnic vein thrombosis occurred more frequently in younger patients (13% vs. 2%, p = 0.0056). Myelofibrotic and leukemic transformation, the most serious complications of myeloproliferative neoplasms (MPN), occurred with similar frequencies in young versus older patients (15% vs. 10%, p = 0.29). Prevention or delay of these complications is currently the most urgent challenge in the care of younger patients with PV.

Entities:  

Mesh:

Year:  2013        PMID: 23245211     DOI: 10.3109/10428194.2012.759656

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  26 in total

Review 1.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 2.  Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.

Authors:  Jamile M Shammo; Brady L Stein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 3.  New Therapeutic Approaches in Polycythemia Vera.

Authors:  Lorenzo Falchi; Kate J Newberry; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

Review 4.  Polycythemia Vera.

Authors:  Jerry L Spivak
Journal:  Curr Treat Options Oncol       Date:  2018-03-07

Review 5.  Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.

Authors:  Jeffrey Patterson-Fortin; Alison R Moliterno
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 6.  Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.

Authors:  Joan How; Amy Zhou; Stephen T Oh
Journal:  Ther Adv Hematol       Date:  2016-12-08

7.  Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera.

Authors:  Jared S Fowles; Joan How; Maggie J Allen; Stephen T Oh
Journal:  Leukemia       Date:  2019-01-11       Impact factor: 11.528

Review 8.  Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.

Authors:  Minas P Economides; Srdan Verstovsek; Naveen Pemmaraju
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

Review 9.  Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

Authors:  Aziz Nazha; Aaron T Gerds
Journal:  Oncologist       Date:  2016-03-14

Review 10.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.